+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Reduction in Human Papillomavirus Vaccine Type Prevalence Among Young Women Screened for Cervical Cancer in an Integrated US Healthcare Delivery System in 2007 and 2012-2013



Reduction in Human Papillomavirus Vaccine Type Prevalence Among Young Women Screened for Cervical Cancer in an Integrated US Healthcare Delivery System in 2007 and 2012-2013



Journal of Infectious Diseases 212(12): 1970-1975



In the United States, human papillomavirus (HPV) vaccine is recommended for 11- or 12-year-olds, and for young adults not previously vaccinated. Early vaccine impact can be measured by reductions in vaccine-type (VT) HPV prevalence. Consecutive residual cervical specimens were retained from women aged 20-29 years at Kaiser Permanente Northwest in 2007, 2012, and 2013. HPV genotypes were determined using L1 consensus polymerase chain reaction with type-specific hybridization to detect 37 types, including VT HPV (HPV type 6, 11, 16, and 18). We compared HPV prevalence in 2007 and 2012-2013, and we evaluated predictors of VT HPV and any-HPV prevalence in 2012-2013. In 2012-2013, 31.9% of 4181 women had initiated HPV vaccination. VT HPV prevalence decreased from 10.6% in 2007 to 6.2% in 2012-2013 (P < .001). In 2012-2013, VT HPV prevalence was significantly lower among those who initiated vaccination <19 years (adjusted prevalence ratio, 0.1; 95% confidence interval, .1-.3) than among those who were not vaccinated, and higher among those who had chlamydia, human immunodeficiency virus, or pregnancy testing in the past year than among those who did not (adjusted prevalence ratio, 1.4; 95% confidence interval, 1.1-1.8). Reduction in VT HPV was found in young women in an integrated healthcare delivery system within 6 years of vaccine introduction, indicating early HPV vaccine impact.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058717805

Download citation: RISBibTeXText

PMID: 26123561

DOI: 10.1093/infdis/jiv342


Related references

Reduction in Vaccine-Type Human Papillomavirus Prevalence Among Women in the United States, 2009-2012. Journal of Infectious Diseases 214(12): 1961-1964, 2016

Type-specific prevalence of Human Papillomavirus in women screened for cervical cancer in Labrador, Canada. International Journal of Circumpolar Health 72(1): 19743, 2013

Type-specific prevalence of human papillomavirus in women screened for cervical cancer in Labrador, Canada. International Journal of Circumpolar Health 72:, 2013

Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact. Cancer Causes and Control 24(2): 403-407, 2013

P3.051Pre-Vaccination Prevalence of Infections with 25 Low-Risk Human Papillomavirus (Hpv) Types Among 1000 Slovenian Women Screened For Cervical Cancer in 2010. Sexually Transmitted Infections 89(Suppl 1): A164.1-A164, 2013

Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States. Mmwr. Morbidity and Mortality Weekly Report 62(29): 591-595, 2013

Human papillomavirus vaccination and subsequent cervical cancer screening in a large integrated healthcare system. American Journal of Obstetrics and Gynecology 216(2): 151.E1-151.E9, 2017

Factors predicting intermediate endpoints of cervical cancer and exposure to human papillomavirus (HPV) infections in young women screened as potential targets for prophylactic HPV vaccination in south of Brazil. European Journal of Obstetrics Gynecology and Reproductive Biology 124(1): 110-118, 2006

Utilization of Cervical Cytology and Human Papillomavirus DNA Tests by 15-27 Million Privately Insured Women, 2007-2013. American Journal of Clinical Pathology 144(Suppl 2): A227-A227, 2015

Prevalence and distribution of human papillomavirus type-16 DNA in pelvic lymph nodes of patients with cervical cancer and in women with no history of cervical abnormality. International Journal of Cancer 52(2): 225-228, 1992

Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Annals of Internal Medicine 148(7): 493-500, 2008

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women. Journal of Adolescent Health 46(2): 142-151, 2010

Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. Journal of Infectious Diseases 208(3): 385-393, 2013

Incidence of genital warts in adolescents and young adults in an integrated health care delivery system in the United States before human papillomavirus vaccine recommendations. Sexually Transmitted Diseases 40(7): 534-538, 2013

Decreasing Trends in Cervical Cancer Incidence among Young Women (1534 Years) in the United States during the Human Papillomavirus (HPV) Vaccine Era. Cancer Epidemiology Biomarkers & Prevention 26(3): 435.3-436, 2017